低分子イノベーターAPI CDMO市場規模、成長と動向分析レポート 2025-2030年

低分子イノベーターAPI CDMO業界の成長は、低分子医薬品の需要増加、製薬会社によるアウトソーシングの増加、そして臨床試験件数の増加に起因しています。さらに、新規低分子イノベーターAPI開発拡大に向けた製薬業界の研究開発投資の増加、新規治療法への需要増加、そしてがんや加齢関連疾患の罹患率増加も、市場成長を牽引する主要な要因となっています。

Small Molecule Innovator API CDMO Market Growth & Trends

The global small molecule innovator API CDMO market size is expected to reach USD 47.14 billion by 2030, registering a CAGR of 6.38% from 2025 to 2030, according to a new report by Grand View Research, Inc. A growing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and a surge in the number of clinical trials are anticipated to influence the market positively. The growing utilization of CDMOs in the pharmaceutical sector stems from various reasons, with cost-effectiveness as the prominent factor. Outsourcing emerges as an efficient strategy for pharmaceutical firms to reduce expenses by sidestepping the necessity for costly infrastructure and equipment investments. CDMOs offer the requisite expertise and infrastructure to deliver drug development and manufacturing services in a financially prudent manner.

世界の低分子イノベーターAPI CDMO市場規模は、2030年までに471億4,000万米ドルに達し、2025年から2030年にかけて6.38%のCAGRを記録すると予想されています。製薬会社の間でのアウトソーシングの傾向の拡大、低分子医薬品の需要の増加、臨床試験数の急増が、市場にプラスの影響を与えると予想されています。製薬分野でCDMOの利用が増えているのはさまざまな理由がありますが、費用対効果が大きな要因となっています。アウトソーシングは、製薬会社がコストのかかるインフラや設備投資の必要性を回避することで経費を削減する効率的な戦略として浮上しています。CDMOは、財務的に賢明な方法で医薬品開発および製造サービスを提供するために必要な専門知識とインフラを提供します。

Furthermore, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules. In addition, several pharmaceutical companies prefer CDMOs to access advanced infrastructure and expertise due to the increasing influx of novel therapies & orphan drugs and higher returns on approved products. Moreover, continuous technological advancements among CDMOs offer innovative small molecule APIs to meet the growing demands for innovation, efficiency, and regulatory compliance in the healthcare industry.

The adoption of advanced technologies by companies enhances drug development, manufacturing processes, and productivity. The increasing demand for new small molecule innovator API in the pharmaceutical industry is encouraging commercial CDMOs to expand their capabilities, which is expected to boost market growth. For instance, in August 2023, Astex announced a research collaboration & license agreement with MSD to classify small molecule candidates with tumor suppressor proteins for cancer treatment. Under the agreement, the company will use its fragment-based drug discovery platform to develop compounds and provide MSD with main compounds for preclinical development & optimization.

Small Molecule Innovator API CDMO Market Report Scope

Small Molecule Innovator API CDMO Market Report Highlights

• The clinical stage type segment led the small molecule innovator API CDMO industry and accounted for 54.56% of global revenue in 2024. The preclinical segment is anticipated to grow at a lucrative CAGR over the forecast period.

• The pharmaceutical segment dominated the market in 2024, accounting for a revenue share of 91.07%. Small-molecule drugs have been the backbone of the pharmaceutical industry for nearly a century. The biotechnology segment’s expansion is driven by rising demand for biotechnology and enhanced molecular efficiency.

• The oncology segment dominated the small molecule innovator API CDMO market in 2024 and is expected to grow at the fastest CAGR of 6.80% during the forecast period. The infectious diseases market has witnessed dynamic trends and scenarios across various disease segments.

• North America small molecule innovator API CDMO market is expected to grow at a CAGR of 5.91% over the forecast period. Asia Pacific held the largest market share of 41.74% in 2024.

Table of Contents

Chapter 1. Research Methodology and Scope

1.1. Market Segmentation & Scope

1.2. Segment Definitions

1.2.1. Stage Type

1.2.2. Customer Type

1.2.3. Therapeutic Area

1.3. Research Methodology

1.4. Information Procurement

1.4.1. Purchased Database

1.4.2. GVR’s Internal Database

1.4.3. Secondary Sources

1.4.4. Primary Research

1.5. Information Or Data Analysis

1.5.1. Data Analysis Models

1.6. Market Formulation & Validation

1.7. Model Details

1.7.1. Commodity Flow Analysis

1.7.2. Parent Market Analysis

1.8. List Of Secondary Sources

1.9. List Of Abbreviations

1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook

2.2. Segment Outlook

2.3. Competitive Insights

Chapter 3. Small Molecule Innovator API CDMO Market Variables, Trends & Scope

3.1. Market Lineage Outlook

3.1.1. Parent Market Outlook

3.1.2. Related/Ancillary Market Outlook

3.2. Market Dynamics

3.2.1. Market Driver Analysis

3.2.1.1. Increasing Demand for Small Molecule Drugs

3.2.1.2. Increasing Outsourcing Trends Among Pharmaceutical Companies

3.2.1.3. Surge In Number of Clinical Trials

3.2.2. Market Restraint Analysis

3.2.2.1. Compliance Issues While Outsourcing

3.2.2.2. Changing Scenarios in Developing Economies

3.3. Technological Landscape

3.3.1. Integration of AI in Small Molecule Innovator API CDMO Market

3.3.1.1. Current Dynamics and Future Trends

3.3.1.1.1. Drug Discovery and Design

3.3.1.1.2. AI-Assisted Drug API Synthesis

3.3.1.1.3. Process Optimization

3.3.1.1.4. Supply Chain Management

3.3.1.1.5. Clinical Trial Optimization

3.3.1.1.6. Regulatory Compliance

3.4. Total Number of Clinical Trials by Phase & Region (2021 – 2024)

3.4.1. Total Number of Clinical Trials by Phase (2021 – 2024)

3.4.2. Total Number of Clinical Trials by Region (2021 – 2024)

3.4.2.1. Percentage of Clinical Trials by Major Countries in North America:

3.4.2.2. Percentage of Clinical Trials by Major Countries in Europe:

3.4.2.3. Percentage of Clinical Trials by Major Countries in Asia Pacific:

3.4.2.4. Percentage of Clinical Trials by Major Countries in Latin America:

3.4.2.5. Percentage of Clinical Trials by Major Countries in the Middle East & Africa:

3.4.2.6. Total Number of Clinical Trials by Therapeutic Area (2021 – 2024)

3.5. Pricing Model Analysis

3.6. Market Analysis Tools

3.6.1. Porter’s Five Analysis

3.6.2. PESTEL by SWOT Analysis

3.6.3. COVID-19 Impact Analysis

Chapter 4. Small Molecule Innovator API CDMO Market: Stage Type Estimates & Trend Analysis

4.1. Small Molecule Innovator API CDMO Market, By Stage Type: Segment Dashboard

4.2. Small Molecule Innovator API CDMO Market, By Stage Type: Movement Analysis

4.3. Small Molecule Innovator API CDMO Market Estimates & Forecasts, By Stage Type, 2018 – 2030

4.4. Preclinical

4.4.1. Preclinical Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

4.5. Clinical

4.5.1. Clinical Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

4.5.2. Phase I

4.5.2.1. Phase I Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

4.5.3. Phase II

4.5.3.1. Phase II Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

4.5.4. Phase III

4.5.4.1. Phase III Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

4.6. Commercial

4.6.1. Commercial Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

Chapter 5. Small Molecule Innovator API CDMO Market: Customer Type Estimates & Trend Analysis

5.1. Small Molecule Innovator API CDMO Market, By Customer Type: Segment Dashboard

5.2. Small Molecule Innovator API CDMO Market, By Customer Type: Movement Analysis

5.3. Small Molecule Innovator API CDMO Market Estimates & Forecasts, By Customer Type, 2018 – 2030

5.4. Pharmaceutical

5.4.1. Pharmaceutical Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

5.4.2. Small

5.4.2.1. Small Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

5.4.3. Medium

5.4.3.1. Medium Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

5.4.4. Large

5.4.4.1. Large Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

5.5. Biotechnology

5.5.1. Biotechnology Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

5.5.2. Small

5.5.2.1. Small Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

5.5.3. Medium

5.5.3.1. Medium Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

5.5.4. Large

5.5.4.1. Large Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

Chapter 6. Small Molecule Innovator API CDMO Market: Therapeutic Area Estimates & Trend Analysis

6.1. Small Molecule Innovator API CDMO Market, By Therapeutic Area: Segment Dashboard

6.2. Small Molecule Innovator API CDMO Market, By Therapeutic Area: Movement Analysis

6.3. Small Molecule Innovator API CDMO Market Estimates & Forecasts, By Therapeutic Area, 2018 – 2030

6.4. Cardiovascular Diseases

6.4.1. Cardiovascular Diseases Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

6.5. Oncology

6.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

6.6. Respiratory Disorders

6.6.1. Respiratory Disorders Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

6.7. Neurology

6.7.1. Neurology Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

6.8. Metabolic Disorders

6.8.1. Metabolic Disorders Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

6.9. Infectious Diseases

6.9.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

6.10. Others

6.10.1. Others Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

Chapter 7. Small Molecule Innovator API CDMO Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2030

7.2. Regional Market Dashboard

7.3. Global Regional Market Snapshot

7.4. North America

7.4.1. North America Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.4.2. U.S

7.4.2.1. Key Country Dynamics

7.4.2.2. Competitive Scenario

7.4.2.3. Regulatory Framework

7.4.2.4. U.S. Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.4.3. Canada

7.4.3.1. Key Country Dynamics

7.4.3.2. Competitive Scenario

7.4.3.3. Regulatory Framework

7.4.3.4. Canada Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.4.4. Mexico

7.4.4.1. Key Country Dynamics

7.4.4.2. Competitive Scenario

7.4.4.3. Regulatory Framework

7.4.4.4. Mexico Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.5. Europe

7.5.1. Europe Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.5.2. UK

7.5.2.1. Key Country Dynamics

7.5.2.2. Competitive Scenario

7.5.2.3. Regulatory Framework

7.5.2.4. UK Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.5.3. Germany

7.5.3.1. Key Country Dynamics

7.5.3.2. Competitive Scenario

7.5.3.3. Regulatory Framework

7.5.3.4. Germany Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.5.4. France

7.5.4.1. Key Country Dynamics

7.5.4.2. Competitive Scenario

7.5.4.3. Regulatory Framework

7.5.4.4. France Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.5.5. Italy

7.5.5.1. Key Country Dynamics

7.5.5.2. Competitive Scenario

7.5.5.3. Regulatory Framework

7.5.5.4. Italy Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.5.6. Spain

7.5.6.1. Key Country Dynamics

7.5.6.2. Competitive Scenario

7.5.6.3. Regulatory Framework

7.5.6.4. Spain Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.5.7. Denmark

7.5.7.1. Key Country Dynamics

7.5.7.2. Competitive Scenario

7.5.7.3. Regulatory Framework

7.5.7.4. Denmark Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.5.8. Sweden

7.5.8.1. Key Country Dynamics

7.5.8.2. Competitive Scenario

7.5.8.3. Regulatory Framework

7.5.8.4. Sweden Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.5.9. Norway

7.5.9.1. Key Country Dynamics

7.5.9.2. Competitive Scenario

7.5.9.3. Regulatory Framework

7.5.9.4. Norway Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.6. Asia Pacific

7.6.1. Asia Pacific Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.6.2. China

7.6.2.1. Key Country Dynamics

7.6.2.2. Competitive Scenario

7.6.2.3. Regulatory Framework

7.6.2.4. China Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.6.3. Japan

7.6.3.1. Key Country Dynamics

7.6.3.2. Competitive Scenario

7.6.3.3. Regulatory Framework

7.6.3.4. Japan Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.6.4. India

7.6.4.1. Key Country Dynamics

7.6.4.2. Competitive Scenario

7.6.4.3. Regulatory Framework

7.6.4.4. India Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.6.5. Australia

7.6.5.1. Key Country Dynamics

7.6.5.2. Competitive Scenario

7.6.5.3. Regulatory Framework

7.6.5.4. Australia Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.6.6. South Korea

7.6.6.1. Key Country Dynamics

7.6.6.2. Competitive Scenario

7.6.6.3. Regulatory Framework

7.6.6.4. South Korea Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.6.7. Thailand

7.6.7.1. Key Country Dynamics

7.6.7.2. Competitive Scenario

7.6.7.3. Regulatory Framework

7.6.7.4. Thailand Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.6.8. Taiwan

7.6.8.1. Key Country Dynamics

7.6.8.2. Competitive Scenario

7.6.8.3. Regulatory Framework

7.6.8.4. Taiwan Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.7. Latin America

7.7.1. Latin America Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.7.2. Brazil

7.7.2.1. Key Country Dynamics

7.7.2.2. Competitive Scenario

7.7.2.3. Regulatory Framework

7.7.2.4. Brazil Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.7.3. Argentina

7.7.3.1. Key Country Dynamics

7.7.3.2. Competitive Scenario

7.7.3.3. Regulatory Framework

7.7.3.4. Argentina Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.8. MEA

7.8.1. MEA Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.8.2. South Africa

7.8.2.1. Key Country Dynamics

7.8.2.2. Competitive Scenario

7.8.2.3. Regulatory Framework

7.8.2.4. South Africa Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.8.3. Saudi Arabia

7.8.3.1. Key Country Dynamics

7.8.3.2. Competitive Scenario

7.8.3.3. Regulatory Framework

7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.8.4. UAE

7.8.4.1. Key Country Dynamics

7.8.4.2. Competitive Scenario

7.8.4.3. Regulatory Framework

7.8.4.4. UAE Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.8.5. Kuwait

7.8.5.1. Key Country Dynamics

7.8.5.2. Competitive Scenario

7.8.5.3. Regulatory Framework

7.8.5.4. Kuwait Market Estimates and Forecasts, 2018 – 2030 (USD Million)

7.8.6. Israel

7.8.6.1. Key Country Dynamics

7.8.6.2. Competitive Scenario

7.8.6.3. Regulatory Framework

7.8.6.4. Israel Market Estimates and Forecasts, 2018 – 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Market Participant Categorization

8.2. Market Position Analysis, 2024 (Heat Map Analysis)

8.3. Company Profiles

8.3.1. Lonza Group Ltd.

8.3.1.1. Company Overview

8.3.1.2. Financial Performance

8.3.1.3. Service Benchmarking

8.3.1.4. Strategic Initiatives

8.3.2. Novo Holdings (Catalent, Inc.)

8.3.2.1. Company Overview

8.3.2.2. Financial Performance

8.3.2.3. Service Benchmarking

8.3.2.4. Strategic Initiatives

8.3.3. Thermo Fisher Scientific, Inc.

8.3.3.1. Company Overview

8.3.3.2. Financial Performance

8.3.3.3. Service Benchmarking

8.3.3.4. Strategic Initiatives

8.3.4. Siegfried Holding AG

8.3.4.1. Company Overview

8.3.4.2. Financial Performance

8.3.4.3. Service Benchmarking

8.3.4.4. Strategic Initiatives

8.3.5. Recipharm AB

8.3.5.1. Company Overview

8.3.5.2. Financial Performance

8.3.5.3. Service Benchmarking

8.3.5.4. Strategic Initiatives

8.3.6. CordenPharma International

8.3.6.1. Company Overview

8.3.6.2. Financial Performance

8.3.6.3. Service Benchmarking

8.3.6.4. Strategic Initiatives

8.3.7. Samsung Biologics

8.3.7.1. Company Overview

8.3.7.2. Financial Performance

8.3.7.3. Service Benchmarking

8.3.7.4. Strategic Initiatives

8.3.8. Labcorp

8.3.8.1. Company Overview

8.3.8.2. Financial Performance

8.3.8.3. Service Benchmarking

8.3.8.4. Strategic Initiatives

8.3.9. Ajinomoto Bio-Pharma Services

8.3.9.1. Company Overview

8.3.9.2. Financial Performance

8.3.9.3. Service Benchmarking

8.3.9.4. Strategic Initiatives

8.3.10. Piramal Pharma Solutions

8.3.10.1. Company Overview

8.3.10.2. Financial Performance

8.3.10.3. Service Benchmarking

8.3.10.4. Strategic Initiatives

8.3.11. Jubilant Life Sciences (Jubilant Biosys Limited)

8.3.11.1. Company Overview

8.3.11.2. Financial Performance

8.3.11.3. Service Benchmarking

8.3.11.4. Strategic Initiatives

8.3.12. WuXi AppTec Co., Ltd.

8.3.12.1. Company Overview

8.3.12.2. Financial Performance

8.3.12.3. Service Benchmarking

8.3.12.4. Strategic Initiatives

List of Tables

Table 1 List of Tables

Table 2 List of Secondary Sources

Table 3 List of Abbreviations

Table 4 Global Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 5 Global Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 6 Global Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 7 Global Small Molecule Innovator API CDMO Market, by Region, 2018 – 2030 (USD Million)

Table 8 North America Small Molecule Innovator API CDMO Market, by Country, 2018 – 2030 (USD Million)

Table 9 North America Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 10 North America Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 11 North America Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 12 U.S. Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 13 U.S. Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 14 U.S. Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 15 Canada Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 16 Canada Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 17 Canada Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 18 Mexico Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 19 Mexico Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 20 Mexico Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 21 Europe Small Molecule Innovator API CDMO Market, by Country, 2018 – 2030 (USD Million)

Table 22 Europe Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 23 Europe Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 24 Europe Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 25 UK Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 26 UK Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 27 UK Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 28 Germany Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 29 Germany Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 30 Germany Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 31 France Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 32 France Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 33 France Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 34 Italy Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 35 Italy Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 36 Italy Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 37 Spain Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 38 Spain Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 39 Spain Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 40 Denmark Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 41 Denmark Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 42 Denmark Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 43 Sweden Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 44 Sweden Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 45 Sweden Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 46 Norway Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 47 Norway Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 48 Norway Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 49 Asia Pacific Small Molecule Innovator API CDMO Market, by Country, 2018 – 2030 (USD Million)

Table 50 Asia Pacific Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 51 Asia Pacific Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 52 Asia Pacific Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 53 China Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 54 China Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 55 China Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 56 Japan Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 57 Japan Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 58 Japan Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 59 India Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 60 India Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 61 India Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 62 Australia Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 63 Australia Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 64 Australia Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 65 South Korea Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 66 South Korea Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 67 South Korea Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 68 Thailand Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 69 Thailand Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 70 Thailand Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 71 Taiwan Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 72 Taiwan Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 73 Taiwan Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 74 Latin America Small Molecule Innovator API CDMO Market, by Country, 2018 – 2030 (USD Million)

Table 75 Latin America Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 76 Latin America Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 77 Latin America Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 78 Brazil Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 79 Brazil Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 80 Brazil Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 81 Argentina Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 82 Argentina Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 83 Argentina Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 84 Middle East & Africa Small Molecule Innovator API CDMO Market, by Country, 2018 – 2030 (USD Million)

Table 85 Middle East & Africa Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 86 Middle East & Africa Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 87 Middle East & Africa Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 88 South Africa Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 89 South Africa Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 90 South Africa Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 91 Saudi Arabia Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 92 Saudi Arabia Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 93 Saudi Arabia Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 94 UAE Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 95 UAE Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 96 UAE Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 97 Kuwait Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 98 Kuwait Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 99 Kuwait Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

Table 100 Israel Small Molecule Innovator API CDMO Market, by Stage Type, 2018 – 2030 (USD Million)

Table 101 Israel Small Molecule Innovator API CDMO Market, by Customer Type, 2018 – 2030 (USD Million)

Table 102 Israel Small Molecule Innovator API CDMO Market, by Therapeutic Area, 2018 – 2030 (USD Million)

List of Figures

Fig. 1 Small molecule innovator API CDMO market segmentation

Fig. 2 Market research process

Fig. 3 Information procurement

Fig. 4 Primary research pattern

Fig. 5 Market research approaches

Fig. 6 Market formulation & validation

Fig. 7 Commodity flow analysis

Fig. 8 Value-Chain-Based Sizing & Forecasting

Fig. 9 QFD model sizing & forecasting

Fig. 10 Bottom-up approach

Fig. 11 Market snapshot

Fig. 12 Segment snapshot 1

Fig. 13 Segment snapshot 2

Fig. 14 Competitive landscape snapshot

Fig. 15 Parent market outlook, 2024 (USD Million)

Fig. 16 Ancillary market outlook, 2024 (USD Million)

Fig. 17 Small Molecule Innovator API CDMO Market Dynamics

Fig. 18 Percentage of clinical trials by major countries in North America

Fig. 19 Percentage of clinical trials by major countries in Europe

Fig. 20 Percentage of clinical trials by major countries in Asia Pacific

Fig. 21 Percentage of clinical trials by major countries in Latin America

Fig. 22 Percentage of clinical trials by major countries in Middle East & Africa

Fig. 23 Porter’s five forces analysis

Fig. 24 Small molecule innovator API CDMO market: PESTEL analysis

Fig. 25 Small Molecule Innovator API CDMO Market: Stage Type outlook and key takeaways

Fig. 26 Small Molecule Innovator API CDMO Market: Stage Type movement analysis

Fig. 27 Preclinical market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 28 Clinical market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 29 Phase I market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 30 Phase II market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 31 Phase III market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 32 Commercial market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 33 Small Molecule Innovator API CDMO Market: Customer Type outlook and key takeaways

Fig. 34 Small Molecule Innovator API CDMO Market: Customer Type movement analysis

Fig. 35 Pharmaceutical market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 36 Small market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 37 Medium market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 38 Large market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 39 Biotechnology market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 40 Small market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 41 Medium market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 42 Large market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 43 Small Molecule Innovator API CDMO Market: Therapeutic Area outlook and key takeaways

Fig. 44 Small Molecule Innovator API CDMO Market: Therapeutic Area movement analysis

Fig. 45 Cardiovascular Diseases market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 46 Oncology market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 47 Respiratory Disorders market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 48 Neurology market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 49 Metabolic Disorders market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 50 Infectious Diseases market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 51 Others market estimates and forecast, 2018 – 2030 (USD Million)

Fig. 52 Regional Marketplace: Key Takeaways

Fig. 53 North America Small Molecule Innovator API CDMO Market estimates and forecasts, 2018–2030 (USD Million)

Fig. 54 Key country dynamics

Fig. 55 U.S. Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 56 Key country dynamics

Fig. 57 Canada Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 58 Key country dynamics

Fig. 59 Mexico Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 60 Europe Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 61 Key country dynamics

Fig. 62 UK Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 63 Key country dynamics

Fig. 64 Germany Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 65 Key country dynamics

Fig. 66 France Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 67 Key country dynamics

Fig. 68 Italy Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 69 Key country dynamics

Fig. 70 Spain Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 71 Key country dynamics

Fig. 72 Denmark outsourcing market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 73 Key country dynamics

Fig. 74 Sweden outsourcing market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 75 Key country dynamics

Fig. 76 Norway outsourcing market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 77 Asia Pacific Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 78 Key country dynamics

Fig. 79 China Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 80 Key country dynamics

Fig. 81 Japan Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 82 Key country dynamics

Fig. 83 India Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 84 Key country dynamics

Fig. 85 Australia Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 86 Key country dynamics

Fig. 87 South Korea Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 88 Key country dynamics

Fig. 89 Thailand Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 90 Key country dynamics

Fig. 91 Taiwan Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 92 Latin America Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 93 Key country dynamics

Fig. 94 Brazil Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 95 Key country dynamics

Fig. 96 Argentina Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 97 MEA Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 98 Key country dynamics

Fig. 99 South Africa Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 100 Fig. Key country dynamics

Fig. 101 Saudi Arabia Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 102 Key country dynamics

Fig. 103 UAE Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 104 Key country dynamics

Fig. 105 Kuwait Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 106 Key country dynamics

Fig. 107 Israel Small Molecule Innovator API CDMO Market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 108 Key company categorization

Fig. 109 Service heat map analysis

Fig. 110 Strategic framework

Grand View Researchについて

Grand View Research（グランドビューリサーチ） はインドと米国を拠点とする市場調査およびコンサルティング会社です。世界中主要 25ヵ国・ 46 業界に関する豊富なデータベースを活用した市場情報は世界の企業団体に活用・引用されています。日本からのレポートのご注文・ご購入相談はお気軽にお問い合わせください。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ 1

ライセンスタイプ 2

ライセンスタイプ 3

ライセンスタイプ 4

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス（インディビジュアルライセンス）
    • 1名のみレポートファイル（印刷不可）をご利用いただけます。
  • チームライセンス
    • 同一企業（関連会社除く）内5名まで共有可能です。印刷可能な電子ファイルをご提供いたします。
  • コーポレートライセンス
    • 同一企業および関連会社内で人数無制限で共有可能です。印刷可能な電子ファイルをご提供いたします。
    • 「関連会社」の範囲についてはお気軽にお問い合わせください。
• 納品形態
  • オンラインダウンロード
• 納期
  • ご注文後1～7営業日　※レポートにより異なります。

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

最新出版レポート

• ARクラウド市場規模、成長と動向分析レポート 2025-2033年
• ノーコードAIプラットフォーム市場規模、成長と動向分析レポート 2025-2033年
• 量子コンピューティングにおけるAI最適化市場規模、成長と動向分析レポート 2025-2033年
• ワイヤレス状態監視システム市場規模、成長と動向分析レポート 2025-2033年
• ゲームストリーミング市場規模、成長と動向分析レポート 2025-2033年

出版レポート一覧